( S ( NP-SBJ-2 ( NP ( NNP Squibb ) ( POS 's ) ) ( NN profit ) ) ( S-ADV ( VP ( VBN estimated ) ( PP ( IN by ) ( NP-LGS ( NNS analysts ) ) ) ( S ( VP ( TO to ) ( VP ( VB be ) ( PP-LOC-PRD ( NP ( QP ( RB about ) ( CD 18 ) ) ( NN % ) ) ( IN above ) ( NP ( NP ( NP ( DT the ) ( QP ( CD 123 ) ( CD million ) ) ) ( CC or ) ( NP ( NP ( CD 1.25 ) ) ( NP-ADV ( DT a ) ( NN share ) ) ) ) ( SBAR ( S ( NP-SBJ ( PRP it ) ) ( VP ( VBD earned ) ( PP-TMP ( IN in ) ( NP ( NP ( DT the ) ( JJ third ) ( NN quarter ) ) ( PP ( IN of ) ( NP ( CD 1988 ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ( VP ( VBD was ) ( NP-PRD ( NP ( DT the ) ( NN result ) ) ( PP ( IN of ) ( NP ( NP ( ADJP ( RB especially ) ( JJ strong ) ) ( NNS sales ) ) ( PP ( IN of ) ( NP ( NP ( PRP$ its ) ( NNP Capoten ) ( NN drug ) ) ( PP ( IN for ) ( S-NOM ( VP ( VBG treating ) ( NP ( NP ( JJ high ) ( NN blood ) ( NN pressure ) ) ( CC and ) ( NP ( JJ other ) ( NN heart ) ( NN disease ) ) ) ) ) ) ) ) ) ) ) ) )